A phase III double-blind placebo-controlled randomized study of dexamphetamine sulfate for fatigue in primary brain tumors patients: An ANOCEF trial (DXA).
Florence Laigle-DonadeyFrançois DucrayMatthieu BooneMamadou Hassimiou DialloDavid HajageCarole RamirezOlivier ChinotDamien RicardJean-Yves DelattrePublished in: Neuro-oncology advances (2019)
Dexamphetamine at a dosage of up to 30 mg/day for 3 months has acceptable tolerability in PBT patients but does not improve fatigue, cognitive function, or QOL.